SCHEMBL2231787

SCHEMBL2231787

Cc1ccc(CCOc2ccc(CN3CCNCC3)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.59
HRH3 Q9Y5N1 6/20 0.55
TSHR P16473 1/20 0.50
LTA4H P09960 1/20 0.49
MEN1 O00255 1/20 0.48
CHRM2 P08172 1/20 0.48
CHRM1 P11229 1/20 0.48
ADRA2C P18825 1/20 0.48
CCR2 P41597 1/20 0.48
CXCL12 P48061 1/20 0.48
BLM P54132 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
SIGMAR1 Q99720 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
KDM1A O60341 1/20 0.47
ACHE P22303 1/20 0.47
RAD52 P43351 1/20 0.47
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2232165 1.00 CXCR4 (0.59) CXCR4HRH3TSHRLTA4HMEN1
Hydrochloric Acid SCHEMBL2233324 0.99 CXCR4 (0.58) CXCR4HRH3TSHRLTA4HMEN1
Hydrochloric Acid SCHEMBL2234356 0.92 CXCR4 (0.57) CXCR4HRH3TSHRLTA4HMEN1
Hydrochloric Acid SCHEMBL2234520 0.92 CXCR4 (0.62) CXCR4HRH3TSHRLTA4HMEN1
SCHEMBL2294267 0.89 SIGMAR1 (0.54) HRH3TSHRLTA4HSIGMAR1
SCHEMBL2236728 0.89 SIGMAR1 (0.54) HRH3TSHRLTA4HSIGMAR1
SCHEMBL2231797 0.89 TSHR (0.54) CXCR4HRH3TSHRLTA4HMEN1
SCHEMBL2231202 0.87 DRD2 (0.53) CXCR4HRH3TSHRLTA4HMEN1
SCHEMBL2233553 0.87 LTA4H (0.50) CXCR4HRH3TSHRLTA4HMEN1
Hydrochloric Acid SCHEMBL2232935 0.86 CXCR4 (0.50) CXCR4HRH3TSHRMEN1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528897-B9 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2015-04-22 EP disclosed
EP-2528897-B1 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2014-10-15 EP disclosed
US-8722663-B2 Di-substituted pyridine derivatives as anticancers OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-05-13 US disclosed
EP-2528897-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS Otsuka Pharmaceutical Co., Ltd. (JP) 2012-12-05 EP disclosed
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-11-08 US disclosed
WO-2011093524-A9 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-12-01 WO disclosed
WO-2011093524-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS TPD52L2, CCNE2, CDK2 CXCR4 1153/4885HRH3 663/4885TSHR 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.